OpenURL Connection Search

Select item for more details and to access through your institution.

CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome.
Published in:
Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.848310
By:
- Zheng, Cankun;
- Xuan, Wanling;
- Chen, Zhenhuan;
- Zhang, Rui;
- Huang, Xiaoxia;
- Zhu, Yingqi;
- Ma, Siyuan;
- Chen, Kaitong;
- Chen, Lu;
- He, Mingyuan;
- Lin, Hairuo;
- Liao, Wangjun;
- Bin, Jianping;
- Liao, Yulin
Publication type:
Article
Bioinformatics exploration of potential common therapeutic targets for systemic and pulmonary arterial hypertension-induced myocardial hypertrophy.
Published in:
Acta Biochimica et Biophysica Sinica, 2023, v. 55, n. 5, p. 831, doi. 10.3724/abbs.2023071
By:
- Lu Chen;
- Mingjue Li;
- Mengjia Shen;
- Yingqi Zhu;
- Kaitong Chen;
- Xiaoxia Huang;
- Cankun Zheng;
- Qiancheng Wang;
- Hairuo Lin;
- Wangjun Liao;
- Jianping Bin;
- Siyuan Ma;
- Yulin Liao
Publication type:
Article
Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research.
Published in:
Frontiers in Pharmacology, 2020, v. 11, p. N.PAG, doi. 10.3389/fphar.2020.561494
By:
- Chen, Lu;
- Ma, Siyuan;
- Hu, Donghong;
- Lin, Hairuo;
- Zhu, Yingqi;
- Chen, Kaitong;
- Chen, Lin;
- Zheng, Cankun;
- Liu, Jichen;
- Liao, Yulin
Publication type:
Article
Lansoprazole alleviates pressure overload-induced cardiac hypertrophy and heart failure in mice by blocking the activation of β-catenin.
Published in:
Cardiovascular Research, 2020, v. 116, n. 1, p. 101, doi. 10.1093/cvr/cvz016
By:
- Lin, Hairuo;
- Li, Yang;
- Zhu, Hailin;
- Wang, Qiancheng;
- Chen, Zhenhuan;
- Chen, Lin;
- Zhu, Yingqi;
- Zheng, Cankun;
- Wang, Yuegang;
- Liao, Wangjun;
- Bin, Jianping;
- Kitakaze, Masafumi;
- Liao, Yulin
Publication type:
Article
Pregnancy-induced physiological hypertrophic preconditioning attenuates pathological myocardial hypertrophy by activation of FoxO3a.
Published in:
Cellular & Molecular Life Sciences, 2023, v. 80, n. 9, p. 1, doi. 10.1007/s00018-023-04909-2
By:
- Xie, Jiahe;
- Zheng, Cankun;
- Shen, Mengjia;
- Lu, Weiling;
- Li, Mingjue;
- He, Mingyuan;
- Chen, Lu;
- Ma, Siyuan;
- Zhu, Yingqi;
- Lin, Hairuo;
- Xiu, Jiancheng;
- Liao, Wangjun;
- Bin, Jianping;
- Liao, Yulin
Publication type:
Article
Growth differentiation factor 11 attenuates cardiac ischemia reperfusion injury via enhancing mitochondrial biogenesis and telomerase activity.
Published in:
Cell Death & Disease, 2021, v. 12, n. 7, p. 1, doi. 10.1038/s41419-021-03954-8
By:
- Chen, Lin;
- Luo, Guangjin;
- Liu, Yameng;
- Lin, Hairuo;
- Zheng, Cankun;
- Xie, Dongxiao;
- Zhu, Yingqi;
- Chen, Lu;
- Huang, Xiaoxia;
- Hu, Donghong;
- Xie, Jiahe;
- Chen, Zhenhuan;
- Liao, Wangjun;
- Bin, Jianping;
- Wang, Qiancheng;
- Liao, Yulin
Publication type:
Article

Found: 6

CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome.

Bioinformatics exploration of potential common therapeutic targets for systemic and pulmonary arterial hypertension-induced myocardial hypertrophy.

Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research.

Lansoprazole alleviates pressure overload-induced cardiac hypertrophy and heart failure in mice by blocking the activation of β-catenin.

Pregnancy-induced physiological hypertrophic preconditioning attenuates pathological myocardial hypertrophy by activation of FoxO3a.

Growth differentiation factor 11 attenuates cardiac ischemia reperfusion injury via enhancing mitochondrial biogenesis and telomerase activity.